(Q44883901)

7 December 2017

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years (English)

1 reference

7 December 2017

1 reference

antibody binding sites

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14568120

23 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00173-4

23 March 2024

3

Valentina Tomassini

1 reference

7 December 2017

2

Carolina Scagnolari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14568120

23 March 2024

4

Claudio Gasperini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14568120

23 March 2024

6

Carlo Pozzilli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14568120

23 March 2024

author name string

Francesca Bellomi

1

1 reference

7 December 2017

Andrea Paolillo

5

1 reference

7 December 2017

Guido Antonelli

7

1 reference

7 December 2017

language of work or name

1 reference

1 November 2003

1 reference

7 December 2017

15 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14568120

full work available at URL

23 March 2024

https://api.elsevier.com/content/article/PII:S0022510X03001734?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00173-4

https://api.elsevier.com/content/article/PII:S0022510X03001734?httpAccept=text/plain

23 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00173-4

Journal of the Neurological Sciences

23 March 2024

published in

1 reference

7 December 2017

215

1 reference

7 December 2017

1-2

1 reference

7 December 2017

3-8

1 reference

Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis

7 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Characterization of four different mammalian-cell-derived recombinant human interferon-beta 1s. Identical polypeptides and non-identical carbohydrate moieties compared to natural ones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Quantitation of neutralization of interferon by antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900173-4

Development of antibodies to interferon beta in patients: technical and biological aspects

7 January 2021

1

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00173-4

23 March 2024

interferon beta-1a

21

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(03)00173-4

23 March 2024

Identifiers

1 reference

7 December 2017

1 reference